The Political Economy of Excessive Pricing in The Pharmaceutical Sector in The EU: A Question of Democracy?
Until recently, excessive pricing as an antitrust violation in the EU was considered a dead letter – there had been
Until recently, excessive pricing as an antitrust violation in the EU was considered a dead letter – there had been
Tim Johnston, Robert O’Donoghue, Sep 11, 2014 The relationship between the institutional design, decision-making powers, and policy-making functions of competition
European Union antitrust regulators have extended their deadline for a decision on General Electric’s 12.4 billion euro bid for Alstom’s
Robert O’Donoghue, May 23, 2013 CPI Europe Column edited by Anna Tzanaki (Competition Policy International) presents: Injunctions And Standard Essential
Robert O’Donoghue, Apr 29, 2011 The rather long and bumpy road towards a minimum level of harmonization of substantive rules
Robert O’Donoghue, Aug 10, 2010 Somewhat fitful attempts at promoting antitrust damages litigation have taken place in the EU in
Louise Macnab, Robert O’Donoghue, Apr 15, 2009 EU competition policy on dominant firms and pharmaceutical parallel trade wholesalers taking advantage
This article is part of a Chronicle. See more from this Chronicle Robert O’Donoghue, May 15, 2008 It is reasonably
© Competition Policy International 2024